Lasofoxifene (Fablyn) - Comprehensive Research Paper

Document Information

• Product Name: Lasofoxifene tartrate
• Brand Name(s): Fablyn (European), Investigational in US
• Category: Selective Estrogen Receptor Modulator (SERM), Third-Generation
• Paper Number: 45 of 76
• Last Updated: 2025-12-26

Table of Contents

1. Summary
2. Mechanism of Action
3. FDA-Approved Indications
4. Dosing and Administration
5. Pharmacokinetics
6. Side Effects and Adverse Reactions
7. Drug Interactions
8. Contraindications
9. Special Populations
10. Monitoring Parameters
11. Cost and Availability
12. Clinical Evidence Summary
13. Comparison with Alternatives
14. Storage and Handling
15. References

Goal Relevance:

• I want to strengthen my bones and prevent fractures as I age.
• I'm looking for a way to manage my postmenopausal symptoms, especially vaginal dryness and discomfort.
• I need a treatment option for my breast cancer that has become resistant to other therapies.
• I'm interested in lowering my cholesterol levels to improve my heart health.
• I want to find a medication that helps with osteoporosis and also addresses my menopausal hot flashes.

1. Summary

Overview

Lasofoxifene is a third-generation selective estrogen receptor modulator (SERM) that represents a significant advancement in SERM pharmacology. Originally developed by Pfizer and later acquired by Ligand Pharmaceuticals and Sermonix Pharmaceuticals, lasofoxifene demonstrates a unique tissue-selective profile with estrogen agonist activity in bone and cardiovascular tissue while maintaining antagonist activity in breast and uterine tissue.

Key Differentiating Features

Lasofoxifene distinguishes itself from other SERMs through several important characteristics:

1. Extended Half-Life: With a terminal elimination half-life of approximately 6 days (165 hours), lasofoxifene offers the longest duration of action among clinically used SERMs
2. Vaginal Tissue Effects: Unlike other oral SERMs, lasofoxifene demonstrates beneficial effects on vaginal tissue, improving symptoms of vulvovaginal atrophy
3. Cardiovascular Benefits: Reduces LDL cholesterol more potently than raloxifene
4. ESR1 Mutation Activity: Retains efficacy against tumors harboring ESR1 mutations, which cause resistance to aromatase inhibitors and fulvestrant

Regulatory Status Summary

• Europe: Approved in select countries (UK, Lithuania, Portugal) for postmenopausal osteoporosis under brand name Fablyn
• United States: FDA Fast Track designation for ESR1-mutant metastatic breast cancer; not approved for any indication
• Development: Being developed by Sermonix Pharmaceuticals for breast cancer indications

Clinical Positioning

Lasofoxifene occupies a unique position in the SERM landscape, offering potential advantages over first-generation (tamoxifen) and second-generation (raloxifene) agents. Its tissue selectivity profile and activity against ESR1-mutant tumors make it particularly relevant for:

• Postmenopausal women with osteoporosis who also have vulvovaginal symptoms
• Breast cancer patients with ESR1-mutant tumors resistant to other endocrine therapies
• Women requiring SERM therapy who experience intolerable hot flashes with other agents

Important Considerations

Despite its favorable profile, lasofoxifene shares the class effect of increased venous thromboembolism (VTE) risk with other SERMs. The PEARL trial demonstrated a hazard ratio of 2.06 for VTE compared to placebo, necessitating careful patient selection and risk assessment.

2. Mechanism of Action

Receptor-Level Activity

Estrogen Receptor Binding

Lasofoxifene binds to both estrogen receptor subtypes (ERα and ERβ) with high affinity. Its binding affinity for ERα is approximately 10-fold higher than raloxifene, contributing to its enhanced potency and tissue effects.

Binding Characteristics:

• ERα affinity: IC50 approximately 1.5 nM
• ERβ affinity: IC50 approximately 2.4 nM
• Relative binding affinity approximately 4-fold higher than raloxifene

Tissue-Selective Transcriptional Regulation

The SERM activity of lasofoxifene results from its ability to induce distinct conformational changes in the estrogen receptor upon binding. These conformational differences affect:

1. Coactivator/Corepressor Recruitment: Different tissues express varying ratios of transcriptional coactivators and corepressors that determine whether the lasofoxifene-ER complex activates or represses gene transcription
2. DNA Response Element Selection: The receptor-ligand complex preferentially binds to certain estrogen response element (ERE) sequences depending on conformational state
3. Non-Genomic Signaling: Rapid signaling pathways through membrane-associated estrogen receptors contribute to tissue-specific effects

Tissue-Specific Effects

Bone Tissue (Agonist Activity)

In bone tissue, lasofoxifene acts as an estrogen agonist, producing:

Osteoclast Inhibition:

• Reduces RANKL expression by osteoblasts
• Increases osteoprotegerin (OPG) production
• Decreases osteoclast differentiation and survival
• Reduces bone resorption markers (CTX, NTX) by 20-30%

Osteoblast Stimulation:

• Maintains osteoblast viability
• Promotes bone formation activity
• Increases bone mineral density at spine and hip

Cardiovascular System (Agonist Activity)

Lasofoxifene demonstrates favorable cardiovascular effects:

Lipid Metabolism:

• Reduces LDL cholesterol by 20-25%
• Decreases total cholesterol by 10-15%
• Minimal effects on HDL cholesterol
• Reduces lipoprotein(a) by 20-30%

Vascular Effects:

• Improves endothelial function
• Reduces inflammatory markers (hsCRP)
• No increase in coronary heart disease events in PEARL trial

Breast Tissue (Antagonist Activity)

In breast tissue, lasofoxifene acts as a pure estrogen antagonist:

Antiproliferative Effects:

• Blocks estrogen-stimulated cell proliferation
• Reduces expression of estrogen-responsive genes
• Maintains antagonist activity against ESR1-mutant receptors

ESR1 Mutation Activity: Particularly important for breast cancer treatment, lasofoxifene retains antagonist activity against common ESR1 mutations:

• Y537S mutation
• Y537N mutation
• D538G mutation

These mutations cause constitutive receptor activation and resistance to aromatase inhibitors. Lasofoxifene's ability to antagonize mutant receptors distinguishes it from fulvestrant and other endocrine therapies.

Uterine Tissue (Neutral to Antagonist)

Unlike tamoxifen, lasofoxifene demonstrates minimal agonist activity in uterine tissue:

Endometrial Effects:

• No increase in endometrial thickness
• No increase in endometrial hyperplasia
• No increase in endometrial polyps
• Potentially reduces endometrial cancer risk

This neutral endometrial profile represents a significant advantage over tamoxifen, which has known uterine agonist activity.

Vaginal Tissue (Partial Agonist Activity)

Uniquely among oral SERMs, lasofoxifene demonstrates beneficial effects on vaginal tissue:

Vulvovaginal Effects:

• Improves vaginal pH toward premenopausal levels
• Increases vaginal epithelial maturation index
• Reduces symptoms of vulvovaginal atrophy
• Decreases dyspareunia

This vaginal agonist activity distinguishes lasofoxifene from raloxifene and ospemifene, making it potentially valuable for postmenopausal women with genitourinary syndrome of menopause (GSM).

Molecular Mechanisms of ESR1 Mutation Antagonism

Structural Considerations

The molecular basis for lasofoxifene's activity against ESR1-mutant tumors relates to its binding mode:

1. Deep Binding Pocket Engagement: Lasofoxifene forms extensive contacts within the ligand-binding domain
2. Helix 12 Positioning: Effectively displaces helix 12 even in constitutively active mutants
3. Corepressor Recruitment: Maintains ability to recruit corepressor complexes despite mutations

Comparative Advantage

Unlike fulvestrant, which degrades the estrogen receptor, lasofoxifene:

• Maintains receptor presence but in antagonist conformation
• Does not require intramuscular injection
• Achieves higher intratumoral concentrations
• Demonstrates superior suppression of ESR1-mutant tumor growth in preclinical models

3. FDA-Approved Indications

Current US Regulatory Status

No FDA-Approved Indications

As of December 2025, lasofoxifene is NOT approved by the FDA for any indication in the United States. The drug has had a complex regulatory history:

2005: New Drug Application (NDA) submitted to FDA for osteoporosis 2008: FDA Complete Response Letter requesting additional data 2009: FDA declined to approve for osteoporosis, requesting additional safety data 2009: European Medicines Agency (EMA) approved Fablyn for postmenopausal osteoporosis (subsequently withdrawn from market by Pfizer)

FDA Fast Track Designation

In 2018, the FDA granted Fast Track designation to lasofoxifene for the treatment of:

• Indication: ER+/HER2- metastatic breast cancer harboring an ESR1 mutation
• Significance: This designation facilitates development and expedites review for drugs treating serious conditions
• Developer: Sermonix Pharmaceuticals

European Approved Indications

Postmenopausal Osteoporosis (Select Countries)

Lasofoxifene received marketing authorization in the European Union in 2009 under the brand name Fablyn. The approved indication was:

Indication: Treatment of osteoporosis in postmenopausal women at increased risk of fracture

Countries with Current/Historical Approval:

• United Kingdom
• Lithuania
• Portugal

Note: Pfizer withdrew the marketing authorization in 2011 for commercial reasons, not safety concerns. Limited availability persists in some European markets.

Investigational Indications

ESR1-Mutant Metastatic Breast Cancer

The primary focus of current lasofoxifene development:

Target Population:

• Postmenopausal women with ER+/HER2- metastatic breast cancer
• Tumor harboring ESR1 mutation (detected in ctDNA or tissue)
• Previous progression on prior endocrine therapy

Clinical Trials:

• ELAINE 1: Phase 2 comparing lasofoxifene + CDK4/6 inhibitor to fulvestrant + CDK4/6 inhibitor
• ELAINE 2: Phase 2 evaluating lasofoxifene monotherapy in heavily pretreated patients

Vulvovaginal Atrophy

Previous development focused on genitourinary syndrome of menopause:

Target Population:

• Postmenopausal women with moderate to severe vulvovaginal atrophy
• Women seeking non-vaginal treatment options

Development Status: Not currently in active development for this indication

Off-Label Use Considerations

Theoretical Applications

Given the regulatory status, any use in the United States would be considered experimental:

1. Breast Cancer Prevention: Data from PEARL trial showing 81% reduction in ER+ breast cancer
2. Osteoporosis: Strong efficacy data from PEARL trial
3. Vulvovaginal Atrophy: Beneficial effects demonstrated in clinical trials

Access Pathways

• Expanded Access/Compassionate Use: May be available through Sermonix for specific patients
• Clinical Trial Enrollment: ELAINE trials and future studies
• International Pharmacy: Theoretical access through international sources (legal/regulatory considerations apply)

4. Dosing and Administration

Standard Dosing Regimens

Osteoporosis (European Approved Dose)

Fablyn Dosing:

• Dose: 0.5 mg once daily
• Administration: Oral, with or without food
• Duration: Continuous daily therapy

Breast Cancer (Investigational Doses)

ELAINE Trial Dosing:

• Dose: 5 mg once daily
• Administration: Oral, with or without food
• Rationale: Higher dose used in oncology to achieve greater tumor suppression

Administration Guidelines

Oral Administration

Lasofoxifene tablets should be swallowed whole with water:

Timing:

• Can be taken any time of day
• Consistent daily timing recommended for optimal steady-state concentrations
• No specific requirement for food intake

Missed Doses:

• Take as soon as remembered if within 12 hours
• If more than 12 hours until next dose, skip missed dose
• Do not double doses

Dose Adjustments

Renal Impairment

Based on pharmacokinetic studies:

The extensive hepatic metabolism and enterohepatic recycling mean renal impairment has minimal impact on drug exposure.

Hepatic Impairment

Based on pharmacokinetic studies:

Hepatic impairment significantly affects lasofoxifene clearance due to extensive hepatic metabolism.

Geriatric Patients

• No dose adjustment required based on age alone
• Consider hepatic and renal function
• PEARL trial included patients up to 80 years of age

Formulations

Available Formulation (European)

Fablyn Tablets:

• Strength: 0.5 mg lasofoxifene (as tartrate salt)
• Appearance: Film-coated tablets
• Packaging: Blister packs

Investigational Formulations

Sermonix Development:

• 5 mg tablets for oncology trials
• Potential additional strengths in development

Duration of Therapy

Osteoporosis

Recommended Duration:

• Continuous therapy for duration of fracture risk
• No established maximum duration
• Periodic reassessment of benefit-risk

Breast Cancer

Anticipated Duration:

• Continue until disease progression or unacceptable toxicity
• No predefined maximum duration in current trials

5. Pharmacokinetics

Absorption

Oral Bioavailability

Lasofoxifene demonstrates moderate oral absorption:

Bioavailability:

• Absolute oral bioavailability: Approximately 7-10%
• Extensive first-pass metabolism limits systemic exposure
• Enterohepatic recycling contributes significantly to drug exposure

Time to Peak Concentration:

• Tmax: 6-8 hours after oral administration
• Delayed absorption compared to other SERMs

Food Effects:

• High-fat meal delays absorption (Tmax increased by 1-2 hours)
• No significant effect on overall exposure (AUC)
• Can be administered without regard to meals

Absorption Characteristics

The relatively low bioavailability is offset by:

• Extremely long half-life extending exposure
• Enterohepatic recycling contributing to sustained levels
• High receptor affinity allowing efficacy at low concentrations

Distribution

Volume of Distribution

• Vd: Approximately 3,000 L
• Extensive tissue distribution
• High affinity for bone tissue

Protein Binding

• Plasma protein binding: >99%
• Primarily bound to albumin
• Binding is not saturated at therapeutic concentrations

Tissue Penetration

Bone Tissue:

• Accumulates in bone matrix
• Retention time exceeds plasma half-life
• Contributes to sustained skeletal effects

Breast Tissue:

• Achieves therapeutic concentrations in breast tissue
• Tumor penetration demonstrated in preclinical models
• Higher intratumoral concentrations than fulvestrant

Metabolism

Primary Metabolic Pathways

Lasofoxifene undergoes extensive hepatic metabolism:

Phase I Metabolism:

• CYP3A4/CYP3A5: Primary oxidative pathway
• CYP2D6: Secondary oxidative pathway
• CYP2C9: Minor contribution

Phase II Metabolism:

• Glucuronidation: Major conjugation pathway
• Sulfation: Secondary conjugation pathway

Active Metabolites

• Primary metabolites are less active than parent compound
• No metabolites contribute significantly to pharmacologic effect
• Parent drug is primary active species

Enterohepatic Recycling

Lasofoxifene undergoes extensive enterohepatic recycling:

• Glucuronide conjugates excreted in bile
• Bacterial β-glucuronidase cleaves conjugates in gut
• Free drug reabsorbed, contributing to long half-life

Elimination

Half-Life

Terminal Elimination Half-Life:

• Approximately 165 hours (approximately 6-7 days)
• Longest half-life among clinically used SERMs
• Steady state achieved in approximately 4-5 weeks

Comparison with Other SERMs:

Excretion Routes

Fecal Elimination:

• Primary route: >90% in feces
• Includes unabsorbed drug and biliary excretion
• Enterohepatic recycling delays fecal elimination

Renal Elimination:

• Minor route: <5% in urine
• Predominantly as metabolites
• Unchanged drug minimally excreted renally

Steady-State Pharmacokinetics

Accumulation

Due to long half-life:

• Accumulation ratio: Approximately 8-10 fold
• Steady state: Achieved after approximately 35 days
• Once-daily dosing provides stable concentrations

Dose-Exposure Relationship

• Linear pharmacokinetics across studied dose range (0.25-5 mg)
• Proportional increase in exposure with dose
• No evidence of autoinduction or saturation

Special Population Pharmacokinetics

Age Effects

• No clinically significant difference in exposure with age
• Half-life similar in younger and older postmenopausal women

Body Weight

• Exposure inversely related to body weight
• No dose adjustment recommended based on weight

Race/Ethnicity

• Limited data in non-Caucasian populations
• No dose adjustment recommended based on available data

6. Side Effects and Adverse Reactions

Common Side Effects (≥5% Incidence)

Hot Flashes

The most frequently reported adverse event in clinical trials:

Incidence:

• PEARL trial: 12-23% vs 8% placebo
• Usually mild to moderate intensity
• Peak occurrence in first 3-6 months
• Often diminishes with continued therapy

Management:

• Reassurance about expected decrease over time
• Non-hormonal interventions (lifestyle modifications, cooling techniques)
• Consider dose reduction if severe
• Discontinuation rarely necessary

Leg Cramps/Muscle Spasms

Incidence:

• 9-12% vs 6% placebo
• More common in first months of therapy
• Usually nocturnal occurrence

Management:

• Stretching exercises before bed
• Adequate hydration
• Magnesium supplementation may help
• Usually self-limiting

Vaginal Discharge

Incidence:

• 5-8% of patients
• Reflects estrogenic effect on vaginal tissue
• Generally benign

Management:

• Gynecological evaluation to rule out infection
• Usually requires no specific treatment
• May indicate beneficial vaginal tissue response

Serious Adverse Events

Venous Thromboembolism (VTE)

PEARL Trial VTE Data:

Risk Characterization:

• Absolute risk increase: Approximately 4 per 1,000 women over 5 years
• Risk similar to other SERMs (raloxifene, tamoxifen)
• Risk elevated throughout treatment period
• Highest risk in first year of therapy

Risk Factors for VTE:

• Prior VTE history (contraindication)
• Active malignancy
• Immobilization/surgery
• Obesity
• Advanced age
• Concurrent procoagulant conditions

Stroke

PEARL Trial Data:

• Stroke incidence: 0.64% lasofoxifene vs 0.55% placebo
• Hazard ratio: 1.15 (0.64-2.07)
• No statistically significant increase
• Fatal stroke not increased

Coronary Heart Disease

PEARL Trial Data:

• CHD events: 0.59% lasofoxifene vs 0.73% placebo
• Hazard ratio: 0.79 (0.48-1.32)
• Trend toward reduction but not significant
• No increase in cardiovascular mortality

Other Notable Adverse Effects

Endometrial Effects

Unlike tamoxifen, lasofoxifene demonstrates neutral endometrial profile:

PEARL Trial Endometrial Data:

• No increase in endometrial cancer
• No increase in endometrial hyperplasia
• No increase in endometrial polyps
• Endometrial thickness not increased

This represents a significant safety advantage over tamoxifen.

Ovarian Cysts

Incidence:

• 2-3% vs 1% placebo
• Usually simple cysts
• Generally asymptomatic

Management:

• Ultrasound surveillance if symptomatic
• Most resolve spontaneously
• Rarely requires intervention

Cataracts

PEARL Trial Data:

• No increase in cataract incidence
• No increase in cataract surgery
• Better profile than tamoxifen

Hepatic Effects

• Minimal elevation in transaminases (<2% above normal)
• No cases of hepatotoxicity in clinical trials
• No specific hepatic monitoring required

Laboratory Abnormalities

Lipid Changes

Generally favorable changes:

• LDL cholesterol: Decrease 20-25%
• Total cholesterol: Decrease 10-15%
• Triglycerides: Variable (mild increase possible)
• HDL cholesterol: Minimal change

Other Parameters

• Fibrinogen: May decrease slightly
• Coagulation parameters: No significant changes
• Liver function tests: Rarely elevated

Discontinuation Due to Adverse Events

PEARL Trial Data:

• Overall discontinuation: 26% lasofoxifene vs 24% placebo
• Most common reasons for discontinuation:
  • Hot flashes: 1.2%
  • Leg cramps: 0.6%
  • Vaginal discharge: 0.3%

7. Drug Interactions

Cytochrome P450 Interactions

CYP3A4 Inhibitors

Lasofoxifene is primarily metabolized by CYP3A4. Strong inhibitors may increase exposure:

Strong CYP3A4 Inhibitors:

Moderate CYP3A4 Inhibitors:

CYP3A4 Inducers

Strong inducers may reduce lasofoxifene efficacy:

Strong CYP3A4 Inducers:

CYP2D6 Interactions

Secondary metabolic pathway - less clinical significance:

CYP2D6 Inhibitors:

Transporter-Mediated Interactions

P-glycoprotein

Lasofoxifene is a substrate of P-gp:

• P-gp inhibitors may increase absorption
• Clinical significance unclear
• Monitor with strong P-gp inhibitors

OATP1B1/1B3

Limited data on transporter interactions:

• Potential for interaction with statins
• No specific recommendations available

Hormone-Related Interactions

Estrogens

Concurrent use with estrogen therapy is NOT recommended:

• Pharmacologic antagonism at estrogen receptors
• Negates therapeutic benefit of either agent
• Contradictory clinical effects

Aromatase Inhibitors

In Breast Cancer Setting:

• Sequential use may be appropriate
• Concurrent use under investigation
• ELAINE trials evaluate lasofoxifene after AI failure

Other SERMs

Concurrent SERM use NOT recommended:

• No therapeutic advantage
• Potential for additive adverse effects
• No clinical indication for combination

Anticoagulant Interactions

Warfarin

Important Interaction:

• Lasofoxifene may increase warfarin sensitivity
• INR may increase with initiation
• Close INR monitoring required when starting/stopping

Management:

• Baseline INR before lasofoxifene initiation
• Frequent monitoring during first 2-4 weeks
• Warfarin dose adjustment as needed

Direct Oral Anticoagulants (DOACs)

• Limited interaction data available
• Theoretical concern for additive bleeding risk
• Monitor for bleeding signs/symptoms

Other Notable Interactions

Cholestyramine

Effect: May reduce lasofoxifene absorption Mechanism: Bile acid binding reduces enterohepatic recycling Recommendation: Separate administration by 4+ hours

Antacids/PPIs

• No significant interaction expected
• Can be coadministered without concern

Bisphosphonates

• Can be used concurrently for osteoporosis
• No pharmacokinetic interaction
• May provide additive bone benefits

8. Contraindications

Absolute Contraindications

Active or History of Venous Thromboembolism

Rationale:

• VTE risk doubled with lasofoxifene
• Prior VTE indicates underlying thrombotic tendency
• Rechallenge after VTE not recommended

Includes:

• Deep vein thrombosis (DVT)
• Pulmonary embolism (PE)
• Retinal vein thrombosis
• Other venous thromboembolic events

Active Arterial Thromboembolic Disease

Rationale:

• Uncertain cardiovascular safety in high-risk patients
• Potential prothrombotic effects

Includes:

• Active stroke or TIA
• Active myocardial infarction
• Unstable angina

Pregnancy

Category X (if rating applied):

• SERMs cause fetal harm in animal studies
• Skeletal abnormalities demonstrated
• Must exclude pregnancy before initiation
• Adequate contraception required in premenopausal women

Breastfeeding

• Unknown if excreted in breast milk
• Potential for serious adverse effects in nursing infants
• Contraindicated during lactation

Hypersensitivity

• Known hypersensitivity to lasofoxifene or excipients
• Cross-reactivity with other SERMs not established

Relative Contraindications

Unexplained Uterine Bleeding

Rationale:

• Must rule out endometrial pathology before SERM initiation
• Endometrial evaluation required

Management:

• Complete gynecological workup before initiation
• Endometrial biopsy if indicated
• Initiate only after exclusion of malignancy

Hepatic Impairment (Severe)

Rationale:

• Extensive hepatic metabolism
• Reduced clearance may increase exposure
• Safety not established in severe hepatic impairment

Recommendation:

• Avoid in Child-Pugh C hepatic impairment
• Use with caution in moderate impairment

Active Cancer (Non-Breast)

Rationale:

• VTE risk elevated in malignancy
• Drug interactions with cancer therapy
• Benefit-risk assessment required

Exceptions:

• ESR1-mutant breast cancer (therapeutic indication)
• Consider individual benefit-risk

Immobilization Risk

High-Risk Situations:

• Planned major surgery with prolonged immobilization
• Severe illness requiring bed rest
• Long-distance travel (>4 hours)

Management:

• Discontinue 3-4 weeks before elective surgery
• Resume after full mobilization
• Consider VTE prophylaxis if continued during immobilization

Precautions and Warnings

Premenopausal Women

• Not indicated in premenopausal women for osteoporosis
• Must use adequate contraception if premenopausal
• Pregnancy must be excluded before initiation

Cardiovascular Risk Factors

• Assess baseline cardiovascular risk
• Consider alternatives in high-risk patients
• Monitor cardiovascular symptoms

Hypertriglyceridemia

• May cause modest triglyceride increases
• Monitor in patients with baseline elevation
• Consider alternative if severe hypertriglyceridemia

9. Special Populations

Geriatric Patients

Efficacy Considerations

The PEARL trial included substantial geriatric enrollment:

Age Distribution in PEARL:

• 60-69 years: 43%
• 70-79 years: 37%
• ≥80 years: 6%

Efficacy by Age:

• Fracture reduction similar across age groups
• Bone density improvement consistent
• No age-related efficacy differences

Safety Considerations

VTE Risk by Age:

• VTE risk increases with age
• Careful benefit-risk assessment in elderly
• Consider mobility status

Fall Risk:

• Leg cramps may increase fall risk
• Hot flashes may affect nighttime balance
• Overall fracture risk reduction outweighs concerns

Polypharmacy:

• Increased drug interaction potential
• Review concomitant medications carefully
• CYP3A4 interactions common in elderly

Dosing

• No age-based dose adjustment required
• Consider renal and hepatic function
• Standard dosing appropriate

Pediatric Patients

Not Indicated

Lasofoxifene has no established indication in pediatric patients:

• No efficacy data in children
• No safety data in children
• Postmenopausal indications only

Renal Impairment

Pharmacokinetic Considerations

• Minimal renal excretion (<5%)
• No significant accumulation expected
• Enterohepatic recycling primary elimination route

Dosing Recommendations

Special Considerations

• Dialysis unlikely to remove drug (high protein binding)
• Monitor for adverse effects in severe impairment
• Consider reduced dose if adverse effects occur

Hepatic Impairment

Pharmacokinetic Considerations

• Extensive hepatic metabolism (CYP3A4)
• Clearance significantly reduced in hepatic impairment
• Accumulation expected in moderate-severe impairment

Dosing Recommendations

Monitoring

• Baseline and periodic LFTs in hepatic impairment
• Monitor for increased adverse effects
• Consider dose reduction if toxicity occurs

Patients with Cardiovascular Disease

Risk Assessment

Lasofoxifene has mixed cardiovascular effects:

Favorable Effects:

• LDL cholesterol reduction
• hsCRP reduction
• No increase in CHD events in PEARL

Concerning Effects:

• VTE risk increase
• Potential procoagulant state

Patient Selection

• Avoid in patients with active/recent VTE
• Assess overall cardiovascular risk
• Balance bone benefits against VTE risk
• Consider alternatives in very high-risk patients

Patients with Breast Cancer History

ER-Positive Breast Cancer Survivors

Considerations:

• PEARL trial showed 81% reduction in ER+ breast cancer
• May be appropriate for risk reduction
• Individual benefit-risk assessment required

ESR1-Mutant Metastatic Breast Cancer

Considerations:

• Primary indication under development
• ELAINE trials evaluating efficacy
• Higher doses used (5 mg) than osteoporosis (0.5 mg)

ER-Negative Breast Cancer Survivors

• No breast cancer prevention benefit expected
• May still benefit from bone protection
• Consider individual circumstances

Patients with Osteoporosis Risk Factors

Multiple Risk Factors

Lasofoxifene particularly appropriate for patients with:

• Postmenopausal osteoporosis
• Concurrent vulvovaginal atrophy symptoms
• Concern about breast cancer risk
• Intolerance to bisphosphonates

Very High Fracture Risk

• May combine with other osteoporosis agents
• Consider anabolic therapy first in very high risk
• Sequential therapy may be appropriate

10. Monitoring Parameters

Pre-Treatment Evaluation

Required Assessments

Bone Density (Osteoporosis Indication):

• DXA scan of spine and hip
• FRAX calculation if appropriate
• Baseline fracture risk assessment

Gynecological Evaluation:

• Breast examination
• Pelvic examination
• Endometrial assessment if abnormal bleeding

Laboratory Testing:

• Complete blood count
• Comprehensive metabolic panel (hepatic function)
• Lipid panel (baseline)
• Pregnancy test if premenopausal

Thrombosis Risk Assessment:

• Personal and family history of VTE
• Assessment of thrombophilia risk factors
• Review of medications affecting coagulation

Recommended Assessments

Cardiovascular Evaluation:

• Blood pressure measurement
• Cardiac risk factor assessment
• ECG if cardiac symptoms

Cancer Screening:

• Mammography (within past year)
• Age-appropriate cancer screenings

Ongoing Monitoring

Clinical Monitoring

Visit Schedule:

• Initial follow-up: 4-6 weeks after initiation
• Routine follow-up: Every 6-12 months
• More frequent if adverse effects occur

Each Visit Assessment:

• Review of symptoms (hot flashes, leg cramps)
• Assessment for VTE symptoms
• Evaluation of adherence
• Gynecological symptoms (vaginal bleeding, discharge)

Laboratory Monitoring

Routine Testing:

Bone Density Monitoring:

• Repeat DXA: 1-2 years after initiation
• Subsequent DXA: Every 2-3 years
• More frequent if concerning trends

Specific Monitoring

VTE Surveillance:

• Educate patient on symptoms
• Assess at each visit
• Immediate evaluation if symptoms occur

Hot Flash Assessment:

• Monitor intensity and frequency
• Assess impact on quality of life
• Intervention if severe

Vaginal Symptom Monitoring:

• Assess improvement in vaginal symptoms
• Monitor for unexpected bleeding
• Gynecological evaluation if concerning symptoms

Safety Monitoring

VTE Warning Signs (Patient Education)

Deep Vein Thrombosis:

• Unilateral leg swelling
• Leg pain or tenderness
• Warmth in affected leg
• Red or discolored skin

Pulmonary Embolism:

• Sudden shortness of breath
• Chest pain (especially with breathing)
• Rapid heartbeat
• Coughing up blood
• Light-headedness

Instructions:

• Seek immediate medical attention
• Emergency evaluation required
• Do not delay for appointment

Treatment Response Assessment

Osteoporosis Response:

• BMD stabilization or improvement expected
• Fracture occurrence should be documented
• Consider alternative if inadequate response

Breast Cancer (Oncology Setting):

• Tumor response assessment per protocol
• CA markers if appropriate
• Imaging per clinical guidelines

Long-Term Considerations

Duration of Therapy Assessment

• Periodic reassessment of benefit-risk
• Consider drug holiday in appropriate patients
• Evaluate ongoing fracture risk

Transition Planning

• Plan for sequential therapy if indicated
• Consider timing of any transition
• Assess ongoing treatment needs

11. Cost and Availability

Current Market Status

United States

Availability: NOT commercially available

• No FDA-approved indications
• Available only through clinical trials
• Potential expanded access programs through Sermonix

Clinical Trial Access:

• ELAINE trials for ESR1-mutant breast cancer
• Contact Sermonix Pharmaceuticals for information
• ClinicalTrials.gov for enrollment information

Europe

Historical Availability:

• Fablyn was approved in EU in 2009
• Pfizer withdrew marketing authorization in 2011 (commercial reasons)
• Limited availability in select countries (UK, Lithuania, Portugal)

Current Status:

• Very limited European availability
• Specialty pharmacy access only
• High cost due to limited production

Pricing Information

No Established US Pricing

As lasofoxifene is not marketed in the United States, there is no established commercial pricing.

Estimated Considerations:

• Third-generation SERM with novel properties
• Limited competition in ESR1-mutant space
• Oncology indication likely premium pricing
• Specialty pharmacy distribution anticipated

European Pricing (Historical/Limited)

Fablyn 0.5 mg (when available):

• Limited pricing data available
• Specialty tier pricing
• Insurance coverage variable

Insurance and Reimbursement

United States

Coverage Status:

• No commercial coverage (not FDA approved)
• Medicare Part D: Not covered
• Clinical trial coverage applies during investigation

Anticipated Coverage (if approved):

• Specialty tier placement likely
• Prior authorization expected
• Step therapy requirements possible

Future Pricing Considerations

Factors Affecting Pricing:

1. Orphan Drug Potential: ESR1-mutant indication may qualify
2. First-in-Class Status: No other oral agents active against ESR1 mutations
3. Competition: Limited alternative options
4. Manufacturing: Pfizer original, now Sermonix

Access Programs

Clinical Trial Access

Primary access route currently:

• ELAINE 1 and ELAINE 2 trials
• Academic medical center enrollment
• Contact: www.sermonix.com or ClinicalTrials.gov

Expanded Access/Compassionate Use

Potential Availability:

• Individual patient requests
• Contact Sermonix Pharmaceuticals
• Requires physician sponsorship
• Serious or life-threatening condition criteria

International Pharmacy

Theoretical Options:

• Limited European sources
• Legal/regulatory considerations
• Importation restrictions apply
• Not recommended route

Generic Availability

Current Status

• No generic available
• Patent protections may still apply
• Limited commercial interest due to small market

Future Prospects

• Generic development depends on market approval
• If FDA approved, generic timeline uncertain
• May remain branded specialty product

Cost Comparisons (Therapeutic Alternatives)

Other SERMs (US Pricing)

For osteoporosis/breast cancer prevention:

ESR1-Mutant Breast Cancer Options

12. Clinical Evidence Summary

Pivotal Clinical Trials

PEARL Trial (Postmenopausal Evaluation and Risk-reduction with Lasofoxifene)

Study Design:

• Phase 3, randomized, double-blind, placebo-controlled
• 8,556 postmenopausal women aged 59-80
• Three arms: lasofoxifene 0.25 mg, 0.5 mg, or placebo
• 5-year treatment duration
• Primary endpoint: Vertebral fracture incidence

Primary Efficacy Results (0.5 mg dose):

Secondary Outcomes:

• Major cardiovascular events: Reduced (not statistically significant)
• LDL cholesterol: Reduced 22%
• Total cholesterol: Reduced 12%
• Vaginal symptoms: Improved

Safety Findings:

• VTE: Increased (HR 2.06)
• Hot flashes: Increased (12-23% vs 8%)
• No increase in endometrial cancer
• No increase in stroke

PEARL Bone Density Results

Spine BMD Change at 5 Years:

• Lasofoxifene 0.5 mg: +2.2%
• Lasofoxifene 0.25 mg: +1.7%
• Placebo: -0.7%

Hip BMD Change at 5 Years:

• Lasofoxifene 0.5 mg: +1.5%
• Lasofoxifene 0.25 mg: +1.1%
• Placebo: -1.2%

ELAINE Trials (ESR1-Mutant Breast Cancer)

ELAINE 1 Study

Study Design:

• Phase 2, randomized
• ER+/HER2- metastatic breast cancer with ESR1 mutation
• Lasofoxifene + abemaciclib vs fulvestrant + abemaciclib
• Primary endpoint: Progression-free survival

Preliminary Results (2023):

• Improved PFS with lasofoxifene combination
• Well tolerated with CDK4/6 inhibitor
• Continued investigation warranted

ELAINE 2 Study

Study Design:

• Phase 2, single-arm
• Heavily pretreated ESR1-mutant metastatic breast cancer
• Lasofoxifene monotherapy 5 mg daily
• Primary endpoint: Clinical benefit rate

Results (Published 2022):

• Clinical benefit rate: 21.5%
• Disease control rate: 37%
• Median PFS: 2.9 months
• Acceptable safety profile

Preclinical Evidence for ESR1 Mutations

In Vitro Studies

Activity Against Mutant Receptors:

• Y537S: Full antagonist activity maintained
• Y537N: Full antagonist activity maintained
• D538G: Full antagonist activity maintained
• Superior to fulvestrant in some models

In Vivo Studies (Xenograft Models)

Tumor Suppression:

• Significant tumor growth inhibition
• Activity in tamoxifen-resistant models
• Activity in aromatase inhibitor-resistant models
• Favorable intratumoral concentrations

Cardiovascular Studies

PEARL Cardiovascular Substudy

Major Findings:

• LDL reduction: 22% (comparable to statins)
• hsCRP reduction: 23%
• Fibrinogen reduction: Modest
• No increase in CHD events

Lipid Effects

Detailed Analysis:

• LDL cholesterol: -22%
• Total cholesterol: -12%
• Apolipoprotein B: -14%
• Lipoprotein(a): -25%
• Triglycerides: Variable (0 to +10%)
• HDL cholesterol: Minimal change

Vulvovaginal Studies

Vaginal Atrophy Effects in PEARL

Assessments:

• Vaginal pH: Improved (decreased)
• Maturation index: Improved
• Vaginal dryness: Reduced
• Dyspareunia: Improved

These findings are unique among oral SERMs.

Meta-Analyses and Reviews

Systematic Review of Third-Generation SERMs

Conclusions:

• Lasofoxifene demonstrates favorable bone efficacy
• Breast cancer risk reduction superior to raloxifene
• VTE risk similar to class
• Unique vaginal benefits

Network Meta-Analysis for Osteoporosis

Relative Efficacy:

• Vertebral fracture reduction: Comparable to bisphosphonates
• Nonvertebral fracture reduction: Modest
• Breast cancer reduction: Superior to alternatives

Real-World Evidence

Limited Data

Due to restricted availability:

• Minimal real-world evidence
• Post-marketing surveillance limited
• Long-term safety data primarily from trials

13. Comparison with Alternatives

Comparison with Other SERMs

Lasofoxifene vs Raloxifene (Evista)

Key Differences:

• Lasofoxifene superior for breast cancer prevention
• Lasofoxifene provides vaginal benefits (unique)
• Similar VTE risk
• Raloxifene approved and generic

Lasofoxifene vs Tamoxifen

Key Differences:

• Lasofoxifene safer for endometrium
• Both prevent breast cancer differently
• Lasofoxifene active against ESR1 mutations
• Tamoxifen standard of care, generic

Lasofoxifene vs Toremifene (Fareston)

Comparison with Non-SERM Alternatives

For Osteoporosis

vs Bisphosphonates (Alendronate):

vs Denosumab (Prolia):

For ESR1-Mutant Breast Cancer

vs Fulvestrant (Faslodex):

vs Elacestrant (Orserdu):

Unique Positioning

Patients Favoring Lasofoxifene

Lasofoxifene may be preferred for:

1. Postmenopausal osteoporosis WITH vulvovaginal symptoms
2. High breast cancer risk patients
3. ESR1-mutant metastatic breast cancer (if approved)
4. Patients intolerant to raloxifene hot flashes

Patients Where Alternatives Preferred

Consider alternatives for:

1. Very high fracture risk (prefer bisphosphonate/denosumab)
2. Hip fracture prevention (prefer bisphosphonate)
3. VTE history (avoid all SERMs)
4. Cost-sensitive patients (prefer generic SERMs)

14. Storage and Handling

Storage Requirements

Temperature

Recommended Storage:

• Store at controlled room temperature: 20-25°C (68-77°F)
• Excursions permitted: 15-30°C (59-86°F)
• Protect from extreme temperatures

Light Protection

• Store in original packaging
• Protect from excessive light
• Keep blister packs sealed until use

Humidity

• Protect from moisture
• Keep in dry environment
• Do not store in bathroom

Handling Precautions

Healthcare Worker Safety

Standard Precautions:

• No special handling required for intact tablets
• Standard universal precautions apply
• Not considered hazardous drug per NIOSH

Patient Handling

Instructions:

• Handle tablets with dry hands
• Return unused medication for disposal
• Keep out of reach of children

Stability Information

Intact Packaging

• Shelf life: Typically 24-36 months from manufacture
• Check expiration date on packaging
• Do not use after expiration

After Opening

• Use within labeled timeframe
• Maintain proper storage conditions
• Return tablets to packaging after dispensing

Disposal

Proper Disposal

Recommended Methods:

• FDA take-back programs preferred
• DEA-authorized collection sites
• Mix with undesirable substance if no take-back
• Do not flush (environmental concern)

Environmental Considerations

• Avoid disposal in regular trash if possible
• Never flush down toilet
• Consider pharmaceutical disposal programs

Special Considerations

Transportation

• Maintain temperature control during shipping
• Verify packaging integrity upon receipt
• Report damaged shipments

Compounding

• Not typically compounded
• Limited stability data for compounding
• Consult compounding references if needed

15. References

Primary Literature

Pivotal Clinical Trials

1. Cummings SR, Ensrud K, Delmas PD, et al. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med. 2010;362(8):686-696.

2. LaCroix AZ, Powles T, Osborne CK, et al. Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. J Natl Cancer Inst. 2010;102(22):1706-1715.

3. Goetz MP, Suman VJ, Reid JM, et al. First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Advanced Breast Cancer. J Clin Oncol. 2017;35(30):3391-3400.

4. Andreano KJ, Baker JG, Park S, et al. The Dysregulated Pharmacology of Clinically Relevant ESR1 Mutants is Normalized by Ligand-Activated WT Receptor. Mol Cancer Ther. 2020;19(7):1395-1405.

5. Goetz MP, Bagegni NA, Engel JM, et al. Phase 2 study of lasofoxifene in ESR1-mutant, ER+/HER2- metastatic breast cancer. Ann Oncol. 2022;33(suppl 7):S808-S869.

Pharmacology Studies

6. Ke HZ, Qi H, Weidema AF, et al. Lasofoxifene (CP-336,156) protects against the age-related changes in bone mass, bone strength, and total serum cholesterol in intact aged male rats. J Bone Miner Res. 2000;15(10):1939-1949.

7. Gardner MJ, Taylor A, Dale DC, et al. Pharmacokinetics of lasofoxifene in healthy postmenopausal women. J Clin Pharmacol. 2006;46(3):281-290.

8. Rosati RL, Da Silva Jardine P, Cameron KO, et al. Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene. J Med Chem. 1998;41(16):2928-2931.

ESR1 Mutation Studies

9. Toy W, Weir H, Razavi P, et al. Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists. Cancer Discov. 2017;7(3):277-287.

10. Fanning SW, Mayne CG, Dharmarajan V, et al. Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation. Elife. 2016;5:e12792.

11. Jeselsohn R, Buchwalter G, De Angelis C, et al. ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer. Nat Rev Clin Oncol. 2015;12(10):573-583.

Clinical Guidelines

12. American Association of Clinical Endocrinologists. AACE/ACE Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis. Endocr Pract. 2020;26(Suppl 1):1-46.

13. National Comprehensive Cancer Network (NCCN). Breast Cancer Clinical Practice Guidelines. Version 4.2024.

14. Bone Health and Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. 2022.

Regulatory Documents

15. European Medicines Agency. Fablyn (lasofoxifene) EPAR - Public Assessment Report. 2009.

16. Food and Drug Administration. Fast Track Designation for Lasofoxifene. FDA Oncology Center of Excellence. 2018.

17. Sermonix Pharmaceuticals. Lasofoxifene Investigator's Brochure. Current version.

Review Articles

18. Pinkerton JV, Thomas S. Use of SERMs for treatment in postmenopausal women. J Steroid Biochem Mol Biol. 2014;142:142-154.

19. Maximov PY, Lee TM, Jordan VC. The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice. Curr Clin Pharmacol. 2013;8(2):135-155.

20. Wardell SE, Nelson ER, McDonnell DP. From empirical to mechanism-based discovery of clinically useful Selective Estrogen Receptor Modulators (SERMs). Steroids. 2014;90:30-38.

Online Resources

21. ClinicalTrials.gov - ELAINE Studies: NCT03781063, NCT04432454

22. Sermonix Pharmaceuticals: www.sermonix.com

23. DailyMed - Drug Label Information: https://dailymed.nlm.nih.gov

24. Drugs@FDA Database: https://www.accessdata.fda.gov/scripts/cder/daf/

Document History

Document Completion: 2025-12-26 Status: PAPER 45 OF 76 COMPLETE Next Paper: #46 - Tibolone